Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation

BACKGROUND: Although osimertinib was approved as adjuvant therapy for lung cancer patients with EGFR mutation in various countries, there is still some ongoing debate as osimertinib has been approved based on disease-free survival (DFS) rather than overall survival (OS). We curated a case series in...

Descripción completa

Detalles Bibliográficos
Autores principales: Osoegawa, Atsushi, Karashima, Takashi, Takumi, Yohei, Sato, Takahiro, Abe, Miyuki, Hashimoto, Takafumi, Sugio, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636461/
https://www.ncbi.nlm.nih.gov/pubmed/37969303
http://dx.doi.org/10.21037/jtd-23-537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636461/
https://www.ncbi.nlm.nih.gov/pubmed/37969303
http://dx.doi.org/10.21037/jtd-23-537

Ejemplares similares